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New-onset jaundice can be a manifestation of multiple pathologic processes including hemolysis, parenchymal liver disease, and
cholestasis; the differential diagnosis is broad and requires a systematic approach. We report a case of a patient who presented with
jaundice after starting minocycline for the treatment of acne vulgaris and rapidly developed fulminant liver failure found to be
due to Wilson’s disease. She also manifested severe Coomb’s negative hemolytic anemia and renal failure secondary to hepatorenal
syndrome. As a bridge to liver transplant, she was successfully treated with plasmapheresis to decrease serum copper in addition
to hemodialysis for acidosis and hyperkalemia. She was able to receive a liver and made a full recovery. The case highlights the use
of plasmapheresis as an adjunctive treatment modality in cases of fulminant liver failure due to Wilson’s disease.

1. Introduction
Wilson’s disease is a rare hereditary disorder of copper
metabolism characterized by accumulation of copper in vital
organs such as the brain and liver, among others. In rare
occasions, the disease can present with fulminant liver failure
that is fatal without an emergent liver transplant. We report a
case of acute Wilson’s disease that rapidly progressed to lifethreatening multiorgan failure and discuss the presentation,
diagnosis, and acute management options that can bridge
patients to liver transplantation.

2. Case Report
A 19-year-old female presented with a two-week history of
worsening scleral icterus, abdominal distension, and fatigue.
She was otherwise healthy, apart from a diagnosis of acne
vulgaris for which she was recently prescribed minocycline.
She denied high-risk behaviors and had no family history of
liver disease. On examination, the patient was afebrile, her

blood pressure was 119/79 mmHg, heart rate was 105 beats
per minute, respiratory rate was 20 breaths per minute, and
her oxygen saturation was 99% on ambient air. She was alert
and oriented with icteric sclera, a mildly distended abdomen
without shifting dullness, and 1+ pitting edema of the lower
extremities.
Laboratory initially revealed mildly elevated transaminases with increased bilirubin, hypoalbuminemia, and elevated international normalized ratio (INR) indicative of hepatocellular liver injury with impaired liver synthetic function
(see Table 1). Hemolysis labs including haptoglobin, direct
Coomb’s test, and lactate dehydrogenase (LDH) were normal.
An abdominal ultrasound revealed mild ascites but was
otherwise normal. She was initially diagnosed with acute
hepatitis of unknown etiology, with the differential diagnosis
including viral hepatitis, drug-induced liver disease since she
had recently started minocycline, autoimmune hepatitis, and
Wilson’s disease.
Further testing revealed negative results for hepatitis A
(IgM and IgG), hepatitis B (surface antigen, e antigen, and
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Table 1: Trend of laboratory values before and after liver transplant.

Hemoglobin
(11.2–15.7 g/dL)
Hematocrit
(34–45%)
MCV
(79–98 fL)
Platelet
(155–369 k/uL)
WBC
(3.7–10.3 k/uL)
BUN
(7–21 mg/dL)
Creatinine
(0.60–1.10 mg/dL)
Sodium
(136–145 mmol/L)
Potassium
(3.7–4.8 mmol/L)
AST
(11–32 U/L)
ALT
(8–33 U/L)
Alkaline phosphatase
(52–144 U/L)
Total bilirubin
(0.2–1.1 mg/dL)
Albumin
(3.3–4.6 g/dL)
INR

Day 1

Day 3

Day 5

Day 6

Day 7
(transplant)

Day 8

Day 13

Day 27

Day 53

11.2

9.6

4.2

9.1

8

7.3

9.5

11.2

12.4

34.9

30

14.8

26.8

23.8

20.8

30.4

34.1

36.8

99

101

131

96

93

89

91

93

90

202

166

162

88

50

32

123

320

238

15.9

14.2

38.1

19.2

7.6

6.4

9.7

11.5

9.7

15

19

41

18

17

15

33

28

19

0.78

1.2

2.63

1.54

1.52

1.13

1.89

1

0.84

135

136

134

141

143

140

139

140

138

4.5

4.3

5.6

4.3

3.9

3.4

3.5

4.3

3.8

159

150

187

323

626

347

57

41

16

89

19

11

230

518

340

122

49

32

47

44

<5

6

28

22

85

70

43

3.4

6.4

32.9

17.2

7.6

4

1.8

0.9

0.4

2.1

2

3.2

2.7

2.4

2.4

2.2

3.7

4.1

1.9

2.1

3.8

4.8

1.8

1.4

1

1

1

core IgG), hepatitis C (IgM and IgG), anti-nuclear antibody,
and anti-smooth muscle antibody, making viral and autoimmune disease extremely unlikely. Her serum ceruloplasmin
level was low at 17 mg/dL (normal 22–50 mg/dL), with serum
and urine copper levels of 273 mcg/dL (normal, 70–175
mcg/dL) and 8719 mcg/day (normal, 15–60 mcg/day), respectively. The findings of acute hepatitis and low ceruloplasmin
level prompted a slit-lamp ophthalmologic exam revealing
copper deposition in Descemet’s membrane of the cornea
consistent with the Kayser-Fleischer (KF) ring, confirming
the diagnosis of Wilson’s disease on day 4.
Clinical deterioration ensued with increasing abdomen
distention and development of hepatic encephalopathy.
Severe hemolysis developed on day 5 with nadir hemoglobin
of 4.2 g/dL, high LDH, undetectable haptoglobin, and negative direct Coomb’s test, in addition to worsening renal and
hepatic function (see Table 1). The patient was subsequently
transferred to the intensive care unit, placed on mechanical
ventilation, and started on renal replacement therapy in the
form of continuous veno-venous hemofiltration (CVVH).
Plasmapheresis using fresh frozen plasma (FFP) was initiated
to reduce the high serum copper level that was believed to be
producing hemolysis and renal tubular damage.

She received three treatments of plasmapheresis removing a total of approximately 7,000 micrograms of copper, in
addition to transfusion for anemia. Her laboratory values
improved by the end of the 48-hour period prior to liver
transplant (see Table 1). Orthotopic liver transplant was
performed on day 7 of hospitalization. The explanted liver
grossly had a tan-yellow hue with nodularity (Figure 2(a)).
Histologic findings revealed chronic inflammatory changes
and extensive bridging fibrosis (Figure 2(b)) with numerous
Mallory bodies (Figure 2(c)). A tissue copper quantification
test showed a level of 1118 mcg/g dry weight (normal 10–
35 mcg/g).
Her hepatic function tests improved and her kidney function normalized. She was discharged on standard immunosuppressive therapy but is expected to have no further
complications related to copper overload.

3. Discussion
Wilson’s disease is a rare autosomal recessive genetic disorder
of copper metabolism characterized by numerous mutations
in the ATP7B gene on chromosome 13. The gene encodes
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Figure 1: Trend of lab values during the acute setting of liver failure
and posttransplant up to a 2-month follow-up.

a transmembrane protein ATPase that functions to transport copper outside the cell, incorporate it as a copperceruloplasmin complex, and excrete excess copper in bile. A
mutation in the ATP7B protein causes cytoplasmic copper
accumulation in many organs including the cornea, brain,
and liver cells [1]. Wilson’s disease affects 1 in 30,000–100,000
individuals and usually presents in the second to third
decades of life. Clinical manifestations are mainly neurologic,
psychiatric, and/or hepatic. Patients who present with neuropsychiatric symptoms (e.g., depression, neurosis, tremor,
choreiform movements, and/or seizures) tend to be older,
and the concurrent liver disease is often felt to be unrelated
and incidental. By contrast, the present patient’s presentation
with fulminant liver failure and no neuropsychiatric findings
occurs in only 5% of cases [2].
The diagnosis of Wilson’s disease can be difficult due
to the variability in clinical manifestations and time course.
Multiple diagnostic scoring systems have been developed but
none have been prospectively validated. Using the system
developed by Ferenci et al. [3], the findings of KF rings,
low ceruloplasmin level, Coomb’s negative hemolytic anemia
(with high serum copper), urinary copper > 2x ULN, and
liver copper quantitative > 5x ULN made the diagnosis of
Wilson’s disease “highly likely,” with a score of 8 out of a
possible 16. In the acute setting, clinical suspicion (e.g., age
of patient, family history, KF rings, and low ceruloplasmin
level) should guide initiation of therapy before fulminant liver
failure ensues. Furthermore, the finding of a ratio of alkaline
phosphatase concentration to total bilirubin concentration of
<2 was identified by Berman et al. [4] in 1991 as providing
100% sensitivity and specificity for fulminant Wilson’s disease
(present in this patient on day 4—see Table 1 and Figure 1).
The validity of this index has not been confirmed by other
studies [5].
Circulating copper is normally loosely bound and transported by albumin, constituting the free copper in healthy
subjects that is greatly elevated in patients with fulminant

(b)

(c)

Figure 2: (a) Gross image of explanted liver with a nodular, tanyellow surface. (b) Histologic section of liver tissue depicting extensive bridging fibrosis. (c) Histologic section depicting ballooning
degeneration and numerous Mallory hyalines indicative of chronic
disease.

liver failure due to Wilson’s disease [6]. The specific trigger for fulminant liver failure is not known, but elevated
serum copper damages both RBC membranes with resultant
intravascular hemolysis and renal tubular cells causing renal
failure. Multiple methods have been used to reduce the
copper load in the acute setting with varied clinical results.
Plasmapheresis with FFP replacement has shown to be
efficacious in rapidly reducing serum copper levels [7]; other
methods that have been used include dialysis, albumin dialysis, and molecular adsorbents recirculating system (MARS)
[8–11]. The chelating agents D-penicillamine and trientine
have been used to promote renal copper excretion in stable
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Wilson’s disease patients; however, with fulminant disease
and rapidly progressive renal failure, the benefit is unclear.
There have been reports of the use of D-penicillamine in
combination with plasmapheresis in the acute setting with
successful outcomes [10]. Nonetheless, the mortality rate in
patients with fulminant liver failure approaches 100% without
emergent liver transplant.
Liver transplantation is indicated for patients with Wilson’s disease in the setting of fulminant liver failure or
chronic liver disease unresponsive to medical management.
Liver transplantation results for Wilson’s disease appear to
be excellent with multiple studies reporting 5-year survivals
>85% and excellent long-term prognosis [11–13]. The largest
of these series was reported from France, including 121
patients transplanted for Wilson’s disease between 1985 and
2009, with the reported survival rate of 87% at 5, 10, and 15
years following transplantation [14].

4. Conclusion
Wilson’s disease should be suspected in young patients
presenting with fulminant liver failure of unknown etiology.
In this setting, plasmapheresis is effective for stabilization of
clinical and laboratory parameters and served as a bridge
to liver transplant. This case further supports the use of
serum copper-reducing modalities in the setting of fulminant
Wilson’s disease.
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